NICE shoots down Kyowa Kirin’s Poteligeo for NHS treatment of mycosis fungoides or Sézary syndrome

pharmafile | July 30, 2020 | News story | Sales and Marketing |  Kyowa Kirin, NICE, pharma 

NICE has issued draft guidance that has shot down Kyowa Kirin’s therapy Poteligeo (mogamulizumab) for use on the NHS in England and Wales for the treatment of previously treated mycosis fungoides or Sézary syndrome, it has emerged.

The noted indication is a variety of non-Hodgkin’s lymphoma caused by cancerous T cells of the blood and lymph nodes and characterised by red patches on the skin that can go on to develop skin tumours

The Institute said that the efficacy of the therapy for treating the condition could not be accurately determined because the design of the clinical trial generating data in support of the application meant that it did not gather the evidence it needed to make a robust decision.

Because of this, any estimate of the therapy’s cost-effectiveness in treating mycosis fungoides or Sézary syndrome would come in far above NICE’s threshold of what could be considered an acceptable use of NHS resources, and as a result NICE said it had no choice but to reject it at this time.

Matt Fellows